Alercell Inc

BiotechnologyBiotechnologyOncologyAI Diagnostics

📍 Bozeman, MT, United States• Founded 2020• 5 employees

StreetZero Signal 63

Be the first to signal interest

About Alercell Inc

Alercell, Inc. is a precision oncology company building autonomous AI diagnostics on a SaaS platform for early leukemia detection, enabled by proprietary epigenetic biomarkers. The company is involved in preventative oncology and the development of cancer detection technologies including genetic detection of cancer and biomarkers for diagnosis. Alercell, Inc. is the parent biotechnology company owning all intellectual property, the LENA platform, the ALER-5 validation dataset, and the full diagnostic and theranostic pipeline. Headquartered in Bozeman, MT, it serves the healthcare sector with a focus on oncology diagnostics and personalized medicine.

LATEST FUNDINGPrivate Placement

$35K

Announced 2026-10-19

TOTAL RAISED$35,000

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Alercell Inc.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES5

FOUNDED2020

HQBozeman, MT, United States

Industry

Biotechnology

Investors

LvlUp Labs LvlUp Ventures

Key highlights

Alercell focuses on early leukemia detection up to 41 months before symptoms using the LENA platform.
The company develops AI-powered molecular diagnostics for leukemia and lung cancer.
It received incubator/accelerator support from LvlUp Labs.
Alercell holds patents and manages strategic partnerships in oncology diagnostics.
Headcount is listed as 5 with Frederic Scheer as CEO and CSO.